Medwell Capital Announces that Mimetogen Completes Patient Recruitment in Phase II Clinical Trial for Dry Eye Disease
News Apr 10, 2011
Medwell Capital Corp. has announced that Mimetogen Pharmaceuticals completed patient recruitment in its phase II clinical trial of MIM-D3 for dry eye disease. A total of 150 patients have been enrolled in the trial with results expected in the second half of 2011.
Under the terms of the agreement announced on February 25, 2011, Medwell will advance a second tranche of funds pursuant to its $2,000,000 financing commitment.
“We are very pleased that Mimetogen is on track to receive its results in the next few months,” said Kevin Giese, President and CEO of Medwell. “If successful, this drug has the potential to become one of the leaders in the very active ophthalmic space, where there have been over 70 licensing deals completed in the past five years.”
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019